Show simple item record

dc.contributor.authorHalabi, S
dc.contributor.authorKelly, WK
dc.contributor.authorMa, H
dc.contributor.authorZhou, H
dc.contributor.authorSolomon, NC
dc.contributor.authorFizazi, K
dc.contributor.authorTangen, CM
dc.contributor.authorRosenthal, M
dc.contributor.authorPetrylak, DP
dc.contributor.authorHussain, M
dc.contributor.authorVogelzang, NJ
dc.contributor.authorThompson, IM
dc.contributor.authorChi, KN
dc.contributor.authorde Bono, J
dc.contributor.authorArmstrong, AJ
dc.contributor.authorEisenberger, MA
dc.contributor.authorFandi, A
dc.contributor.authorLi, S
dc.contributor.authorAraujo, JC
dc.contributor.authorLogothetis, CJ
dc.contributor.authorQuinn, DI
dc.contributor.authorMorris, MJ
dc.contributor.authorHigano, CS
dc.contributor.authorTannock, IF
dc.contributor.authorSmall, EJ
dc.date.accessioned2019-05-02T09:24:04Z
dc.date.issued2016-05
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 34 (14), pp. 1652 - 1659
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3215
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.2015.65.7270
dc.description.abstractPurpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials.Patients and methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases.Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with men with liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled hazard ratios for death in men with lung metastases compared with men with bone with or without LN metastases and in men with any liver metastases compared with men with lung metastases were 1.14 (95% CI, 1.04 to 1.25; P = .007) and 1.52 (95% CI, 1.35 to 1.73; P < .0001), respectively.Conclusion Specific sites of metastases in men with mCRPC are associated with differential OS, with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. These data may help in treatment decisions, the design of future clinical trials, and understanding the variation in biology of different sites of metastases in men with mCRPC.
dc.formatPrint-Electronic
dc.format.extent1652 - 1659
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectBone Neoplasms
dc.subjectLiver Neoplasms
dc.subjectLung Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectRandomized Controlled Trials as Topic
dc.subjectClinical Trials, Phase III as Topic
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleMeta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/jco.2015.65.7270
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue14
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume34en_US
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record